Molecule
Lifitegrast is a lymphocyte function-associated antigen-1 antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED). It is available as eye drops and powder for ophthalmic solution. MedsAcross supplies Lifitegrast for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Xiidra ® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). Xiidra (lifitegrast ophthalmic solution) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED).
Source: US FDA prescribing information
Lifitegrast binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in DED is not known.
Source: US FDA prescribing information
Instill one drop of Xiidra twice daily (approximately 12 hours apart) into each eye using a single-use container. Discard the single-use container immediately after using in each eye. Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration. One drop twice daily in each eye (approximately 12 hours apart).
Source: US FDA prescribing information
Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients in the formulation. Hypersensitivity.
Source: US FDA prescribing information
The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity The most common adverse reactions (incidence 5%-25%) following the use of Xiidra were instillation-site irritation, dysgeusia, and decreased visual acuity.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F). Store single-use containers in the original foil pouch.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Lifitegrast, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Xiidra 50 mg/mL eye dropsOphthalmic | Bausch & Lomb | US FDA | Available on request |
| Lifitegrast 50 mg/mL powder for ophthalmic solutionOphthalmicGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 2 presentations of Lifitegrast and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Lifitegrast, including Xiidra.
Yes. The US FDA first approved Lifitegrast on 11 July 2016, according to Drugs@FDA.
No listed presentation of Lifitegrast is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lifitegrast is classified under ATC code S01XA25 (Lifitegrast).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.